<?xml version="1.0" encoding="UTF-8"?>
<p>Experimentation of drugs for COVID-19 management should certainly start to screen for efficacy and safety of clinically assessed MERS- and/or SARS-CoVs inhibitors, although some precautions derive from the still unexplored properties of the novel COVID-19 virus [
 <xref rid="B16-ijms-21-05145" ref-type="bibr">16</xref>]. Indeed, the RNA-dependent RNA polymerase (RdRp) sequence of SARS-CoV2 shares 96% identity to SARS-CoV [
 <xref rid="B51-ijms-21-05145" ref-type="bibr">51</xref>]. This, in particular, suggests that drugs targeting SARS-CoV RdRp might exhibit similar efficacy for SARS-CoV2 RdRp [
 <xref rid="B51-ijms-21-05145" ref-type="bibr">51</xref>].
</p>
